Get startedLog in
    Picture of Lexagene Holdings logo

    LXG.H — Lexagene Holdings Income Statement

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Lexagene Holdings, fiscal year end - February 28th, USD millions except per share, conversion factor applied.

    2018
    February 28th
    2019
    February 28th
    2020
    February 29th
    2021
    February 28th
    2022
    February 28th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue0000.0580.075
    Cost of Revenue
    Gross Profit———-0.101-0.468
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Total Operating Expenses3.988.327.59.9510.7
    Operating Profit-3.98-8.32-7.5-9.89-10.6
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-4.01-8.32-7.5-9.89-10.6
    Net Income After Taxes-4.01-8.32-7.5-9.89-10.6
    Net Income Before Extraordinary Items
    Net Income-4.01-8.32-7.5-9.89-10.6
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-4.01-8.32-7.5-9.89-10.6
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.076-0.131-0.098-0.097-0.089